Core Viewpoint - The article discusses the effectiveness, safety, and usage guidelines of Semaglutide, a GLP-1 receptor agonist, for weight loss and its implications for patients with obesity and related comorbidities [5]. Weight Loss Efficacy - In the OASIS 1 study, patients taking oral Semaglutide 50mg lost an average of 17.4% (18.34 kg) of their body weight over 68 weeks [6]. - The OASIS 4 study showed that patients taking oral Semaglutide 25mg lost an average of 13.6% (14.4 kg) over 64 weeks, with potential weight loss reaching 16.6% (17.6 kg) if all participants completed the treatment [7]. Side Effects - Approximately 30% of patients reported gastrointestinal side effects such as nausea, vomiting, and diarrhea, which were mostly mild to moderate and tended to resolve over time [8]. - Semaglutide has shown good safety in elderly patients and those with renal impairment, although caution is advised for patients with severe renal dysfunction [8][9]. Usage Guidelines - Semaglutide should be taken at least 30 minutes before the first meal of the day, using no more than 118ml of plain water for swallowing [10]. - The starting dose is recommended at 3mg once daily for 30 days, followed by an increase to 7mg once daily, with a maximum dose of 14mg if necessary [12][13]. Lifestyle Changes - Weight loss should not solely focus on dieting; a balanced diet with adequate protein intake and regular physical activity is essential [15][18]. - The article emphasizes the importance of not consuming fewer than 1200 calories daily and suggests a "small meals" approach to avoid binge eating [15][17]. Mechanism of Action - Semaglutide lowers blood sugar through a glucose-dependent mechanism, improving beta-cell function and insulin resistance while suppressing glucagon secretion [19]. - It mimics GLP-1 to regulate appetite and prolong satiety by slowing gastric emptying [20][21]. Other Therapeutic Effects - Semaglutide has been shown to significantly lower blood sugar levels and has additional benefits such as weight loss, blood pressure reduction, and lipid regulation [29]. - In the PIONEER 6 study, it demonstrated a 51% reduction in cardiovascular death risk compared to placebo in patients with type 2 diabetes and cardiovascular risk factors [30]. Advantages of Oral Formulation - The oral formulation of Semaglutide is easier to store and transport compared to injectable forms, which require strict cold chain logistics [31][32]. - It is also more convenient for patients who may have a fear of injections [33]. Risk of Hypoglycemia - Semaglutide's glucose-dependent mechanism means it does not cause hypoglycemia in individuals with normal blood sugar levels, making it a safer option for weight loss [34]. Weight Regain After Discontinuation - A study indicated that 18% of patients regained weight after stopping Semaglutide, while 56% maintained or continued to lose weight [35].

越来越多人开始使用司美格鲁肽减肥，但是使用时，仍有很多疑问。现在我们就来解答关于 口服 司美格鲁肽片的10大常见问题，帮助你更安 全、更有效地达到减重目标。 ▍ 能减多少斤？ 目前全球范围内口服剂型的司美格鲁肽尚未获批用于减重，国内外处于3期临床试验阶段。 在2023年5月公布的OASIS 1研究中，试验基线平均 体重为 105.4 kg，在 667 名成年肥胖症或超重并伴有至少一种合并症的患者中， 口服司美格鲁肽50mg组患者68周体重平均减轻 17.4%（18.34kg） 。 在最新的OASIS 4研究公布了25mg口服司美格鲁肽的减重III期研究结果。这项研究为期64周，入组307名患者，基线体重105.9千克。结果显 示，口服司美格鲁肽组的体重平均下降了13.6%（14.4kg）。 若所有受试者完成治疗，口服司美格鲁肽组的减重幅度可达到 16.6%（17.6kg）。 此外，司美格鲁肽在整个研究过程中显示了良好的安全性和耐受性。 从现有数据来看，要达到与注射版相似的减重效果，口服版司美格鲁肽的剂量可能需要高达每日25mg甚至50mg，而目前市场上口服版司美格 鲁肽的最高剂量仅为14mg。此外， 不建议超 ...